Michael Franken

Chief Business Officer

Michael brings over 25 years of biotech industry experience and strong business leadership in immunology, rare diseases, and transplant and hematology.


Prior to joining EvolveImmune, Michael was the Chief Business Officer at LogicBio Therapeutics Inc., a public biotech company focused on developing novel genomics medicines for patients with early onset genetic diseases. Until its acquisition by AstraZeneca, Michael was a member of the executive leadership team with responsibility for the company’s business development, strategy and commercial functions with a focus on executing strategic business deals, including the execution of several collaboration and license agreements with large pharmaceutical companies.


Previously, Michael co-founded and managed multiple biotech start-ups, and was in senior leadership roles at Momenta Pharmaceuticals (now Johnson & Johnson), Radius Health and Genzyme Corporation (now Sanofi). During his more than 10-year tenure at Genzyme, Michael held progressively senior positions in corporate development and deal making, drug development and as VP and General Manager, Transplant, was successful in driving significant growth of Genzyme’s commercial transplant business.


Michael received his MD degree from the University of Heidelberg, Germany and his Master’s degree in Health Policy and Management from the Harvard School of Public Health.